Special Issue

Technological Development for Advances in Cancer Research and Precision Oncology

Message from the Guest Editors

Innovations in a wide variety of technologies have accelerated cancer research and transformed clinical oncology. Applications of machine learning and advanced bioinformatics have made progressive breakthroughs in high-dimensional data analytics for cancer prediction. Novel methodologies for the isolation and analysis of extracellular vesicles, cell-free DNA/RNA/protein, circulating tumor cells, and molecular typing have emerged for clinical utility in detection and monitoring of cancer. Advances in single-cell profiling, genome editing, three-dimensional printing, and organoid technology have enhanced our understanding of cancer biology and the development of diagnostic tools and therapeutics. Multi-platform molecular analyses along with the development of targeted agents have led to achievement of personalized cancer therapy. Molecular, cellular, and organismal engineering have had a major impact on basic and translational cancer research. Advances in nanotechnology, molecular probes, spectrometry, and cryo-electron microscopy, as well as applications of biosensors, robotics, and radiation sciences, have accelerated the progress against cancer.

Guest Editors

Dr. Nelson Yee

Dr. Ilias Georgakopoulos-Soares

Dr. Fenglong Ma

Deadline for manuscript submissions

31 December 2025

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/185509

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)